keyword
https://read.qxmd.com/read/38499505/developing-guidance-for-donor-intervention-randomized-controlled-trials-initial-discussions-from-the-canada-united-kingdom-2022-workshop
#1
JOURNAL ARTICLE
Marat Slessarev, Katie L Bain, John Basmaji, Tom D Blydt-Hansen, Jessie Cooper, Frédérick D'Aragon, Lorenzo Del Sorbo, Amy Evans, Anthony C Gordon, Gail Klein, Maureen O Meade, Nicholas Murphy, Helen L Thomas, Matthew J Weiss, Charles Weijer, Dan Harvey
BACKGROUND: Donor interventions, including medications, protocols, and medical devices administered to donors, can enhance transplantable organ quality and quantity and maximize transplantation success. However, there is paucity of high-quality evidence about their effectiveness, in part because of ethical, practical, and regulatory challenges, and lack of guidance about conduct of donor intervention randomized controlled trials (RCTs). METHODS: With the vision to develop authoritative guidance for conduct of donor intervention RCTs, we convened a workshop of Canadian-United Kingdom experts in organ donation and transplantation ethics, research, and policy to identify stakeholders, explore unique challenges, and develop research agenda to inform future work in this promising field...
March 19, 2024: Transplantation
https://read.qxmd.com/read/38487109/advancements-in-periodontal-regeneration-a-comprehensive-review-of-stem-cell-therapy
#2
REVIEW
Tanvi Bharuka, Amit Reche
Periodontal disease, characterized by inflammation and infection of the supporting structures of teeth, presents a significant challenge in dentistry and public health. Current treatment modalities, while effective to some extent, have limitations in achieving comprehensive periodontal tissue regeneration. This comprehensive review explores the potential of stem cell therapy in advancing the field of periodontal regeneration. Stem cells, including mesenchymal stem cells (MSCs) and induced pluripotent stem cells (iPSCs), hold promise due to their immunomodulatory effects, differentiation potential into periodontal tissues, and paracrine actions...
February 2024: Curēus
https://read.qxmd.com/read/38471973/anti-obesity-medications-current-and-futurean-overview-of-therapeutic-options-of-obesity-management-in-india-the-integrated-diabetes-and-endocrinology-academy-idea-2023-congress-update
#3
REVIEW
Subir Ray, Nitin Kapoor, Neeta Deshpande, Sanjay Chatterjee, Janardanan Kumar, Om Tantia, Ghanshyam Goyal, Jagat Jyoti Mukherjee, Awadhesh Kumar Singh
INTRODUCTION: With newer anti-obesity medications (AOMs) being introduced at a rapid pace, it is prudent to make a concise and updated clinical practice document that may help busy clinicians in daily clinical practice. A group of metabolic physicians, diabetologists, endocrinologists, and bariatric surgeons assembled during the Integrated Diabetes and Endocrine Academy 2023 Congress (IDEACON, July 2023, Kolkata, India) to compile an update of pharmacotherapeutic options for managing people with obesity in India...
March 12, 2024: Expert Review of Clinical Pharmacology
https://read.qxmd.com/read/38454445/s100a9-cd14-monocytes-contribute-to-anti-pd-1-immunotherapy-resistance-in-advanced-hepatocellular-carcinoma-by-attenuating-t-cell-mediated-antitumor-function
#4
JOURNAL ARTICLE
Xiaoxuan Tu, Longxian Chen, Yi Zheng, Chenglin Mu, Zhiwei Zhang, Feiyu Wang, Yiqing Ren, Yingxin Duan, Hangyu Zhang, Zhou Tong, Lulu Liu, Xunqi Sun, Peng Zhao, Lie Wang, Xinhua Feng, Weijia Fang, Xia Liu
BACKGROUND: The paucity of reliable biomarkers for predicting immunotherapy efficacy in patients with advanced hepatocellular carcinoma (HCC) has emerged as a burgeoning concern with the expanding use of immunotherapy. This study endeavors to delve into the potential peripheral biomarkers capable of prognosticating efficacy in HCC patients who are poised to receive anti-PD-1 monotherapy within the phase III clinical trial, KEYNOTE394. Additionally, we sought to elucidate the underlying molecular mechanisms for resistance to immune checkpoint blockade (ICB) and propose innovative combination immunotherapy strategies for future clinical application...
March 8, 2024: Journal of Experimental & Clinical Cancer Research: CR
https://read.qxmd.com/read/38376039/neural-correlates-of-fine-motor-grasping-skills-longitudinal-insights-into-motor-cortex-activation-using-fnirs
#5
JOURNAL ARTICLE
Xiaoli Li, Minxia Jin, Nan Zhang, Wei Hongman, LianHui Fu, Qi Qi
BACKGROUND: Motor learning is essential for performing specific tasks and progresses through distinct stages, including the rapid learning phase (initial skill acquisition), the consolidation phase (skill refinement), and the stable performance phase (skill mastery and maintenance). Understanding the cortical activation dynamics during these stages can guide targeted rehabilitation interventions. METHODS: In this longitudinal randomized controlled trial, functional near-infrared spectroscopy was used to explore the temporal dynamics of cortical activation in hand-related motor learning...
January 2024: Brain and Behavior
https://read.qxmd.com/read/38356795/recent-progress-of-nanomedicine-in-managing-dry-eye-disease
#6
REVIEW
Zeen Lv, Su Li, Guixiang Zeng, Ke Yao, Haijie Han
BACKGROUND: Dry eye disease (DED) is a commonly reported ocular complaint that has garnered significant attention in recent research. The global occurrence of DED ranges from 5% to 50%, impacting a substantial proportion of individuals worldwide with increasing frequency. Although topical administration remains the mainstream drug delivery method for ocular diseases, it suffers from drawbacks such as low bioavailability, rapid drug metabolism, and frequent administration requirements...
2024: Adv Ophthalmol Pract Res
https://read.qxmd.com/read/38355079/fractal-calculus-in-tumor-growth-simulations-the-proof-is-in-the-pudding
#7
JOURNAL ARTICLE
Heiko Enderling
Mathematical modeling in oncology has a long history. Recently, mathematical models and their predictions have made inroads into prospective clinical trials with encouraging results. The goal of many such modeling efforts is to make predictions, either to clinician's choice therapy or into "optimal" therapy - often for individual patients. The mathematical oncology community rightfully puts great hope into predictive modeling and mechanistic digital twins - but with this great opportunity comes great responsibility...
February 12, 2024: Bio Systems
https://read.qxmd.com/read/38317479/efficacy-safety-and-feasibility-of-the-treatment-of-intrauterine-pathologies-with-the-mini-resectoscope-a-systematic-review
#8
REVIEW
Andrea Etrusco, Antonio Simone Laganà, Vito Chiantera, Sandro Gerli, Jose Carugno, Felice Sorrentino, Gaetano Riemma, Amerigo Vitagliano, Alessandro Favilli
BACKGROUND: Hysteroscopy represents the gold standard for the diagnosis and treatment of intrauterine pathologies. The advent of the mini-resectoscope heralded a new era in intrauterine surgery, both in inpatient and outpatient settings. OBJECTIVES: To evaluate the effectiveness, safety, and feasibility of the mini-resectoscope for the treatment of intrauterine pathologies. SEARCH STRATEGY: Electronic databases were searched for English-language trials describing surgical procedures for uterine pathologies performed with a mini-resectoscope until 30 April 2023...
February 5, 2024: International Journal of Gynaecology and Obstetrics
https://read.qxmd.com/read/38295415/prediction-of-cognitive-conflict-during-unexpected-robot-behavior-under-different-mental-workload-donditions-in-a-physical-human-robot-collaboration
#9
JOURNAL ARTICLE
Alka Rachel John, Avinash K Singh, Klaus Gramann, Dikai Liu, Chin-Teng Lin
Brain-Computer Interface (BCI) technology is poised to play a prominent role in modern work environments, especially a collaborative environment where humans and machines work in close proximity, often with physical contact. In a physical human robot collaboration (pHRC), the robot performs complex motion sequences. Any unexpected robot behavior or faulty interaction might raise safety concerns. Error-related potentials, naturally generated by the brain when a human partner perceives an error, have been extensively employed in BCI as implicit human feedback to adapt robot behavior to facilitate a safe and intuitive interaction...
January 31, 2024: Journal of Neural Engineering
https://read.qxmd.com/read/38245210/rationale-and-design-of-the-nephrotic-syndrome-study-network-neptune-match-in-glomerular-diseases-designing-the-right-trial-for-the-right-patient-today
#10
JOURNAL ARTICLE
Howard Trachtman, Hailey Desmond, Amanda L Williams, Laura H Mariani, Sean Eddy, Wenjun Ju, Laura Barisoni, Heather K Ascani, Wendy R Uhlmann, Cathie Spino, Lawrence B Holzman, John R Sedor, Crystal Gadegbeku, Lalita Subramanian, Chrysta C Lienczewski, Tina Manieri, Scott J Roberts, Debbie S Gipson, Matthias Kretzler
Glomerular diseases are classified using a descriptive taxonomy that is not reflective of the heterogeneous underlying molecular drivers. This limits not only diagnostic and therapeutic patient management, but also impacts clinical trials evaluating targeted interventions. The Nephrotic Syndrome Study Network (NEPTUNE) is poised to address these challenges. The study has enrolled >850 pediatric and adult patients with proteinuric glomerular diseases who have contributed to deep clinical, histologic, genetic, and molecular profiles linked to long-term outcomes...
February 2024: Kidney International
https://read.qxmd.com/read/38216288/clinical-trajectories-of-hand-function-impairment-in-systemic-sclerosis-an-unmet-clinical-need-across-disease-subsets
#11
JOURNAL ARTICLE
Enrico De Lorenzis, Vishal Kakkar, Stefano Di Donato, Michelle Wilson, Theresa Barnes, Chris Denton, Emma Derrett-Smith, Karen Douglas, Philip Helliwell, Ariane L Herrick, Benazir Saleem, Muhammad Nisar, Catherine Morley, Lorraine Green, Begonya Alcacer-Pitarch, Francesco Del Galdo
BACKGROUND: Hand involvement is an early manifestation of systemic sclerosis (SSc), culprit of diagnosis and classification, and recognised major driver of disability. Impairment of hand function burdens both limited and diffuse cutaneous subsets and therefore could be targeted as 'basket' endpoint in SSc. Nevertheless, its natural history in current standard of care is not well characterised, limiting the design of targeted trials. The aim of this study is to describe prevalence, natural history and clinical factors associated with hand function deterioration in a longitudinal, multicentre, observational SSc cohort...
January 12, 2024: RMD Open
https://read.qxmd.com/read/38201581/acvr1-a-novel-therapeutic-target-to-treat-anemia-in-myelofibrosis
#12
REVIEW
Andrea Duminuco, Helen T Chifotides, Sebastiano Giallongo, Cesarina Giallongo, Daniele Tibullo, Giuseppe A Palumbo
Activin receptor type I (ACVR1) is a transmembrane kinase receptor belonging to bone morphogenic protein receptors (BMPs). ACVR1 plays an important role in hematopoiesis and anemia via the BMP6/ACVR1/SMAD pathway, which regulates expression of hepcidin, the master regulator of iron homeostasis. Elevated hepcidin levels are inversely associated with plasma iron levels, and chronic hepcidin expression leads to iron-restricted anemia. Anemia is one of the hallmarks of myelofibrosis (MF), a bone marrow (BM) malignancy characterized by BM scarring resulting in impaired hematopoiesis, splenomegaly, and systemic symptoms...
December 28, 2023: Cancers
https://read.qxmd.com/read/38197535/the-national-institutes-of-health-investigation-of-co-occurring-conditions-across-the-lifespan-to-understand-down-syndrome-include-project-accelerating-research-discoveries-for-people-with-down-syndrome-across-the-lifespan
#13
REVIEW
Sujata Bardhan, Huiqing Li, Erika Tarver, Charlene Schramm, Marishka Brown, Linda Garcia, Bryanna Schwartz, Anna Mazzucco, Nikila Natarajan, Elizabeth Walsh, Laurie Ryan, Gail Pearson, Melissa A Parisi
The National Institutes of Health (NIH) has a long-standing history of support for research in Down syndrome (DS). In response to a 2018 congressional directive for a trans-NIH initiative to address medical issues in DS, NIH launched the INCLUDE Project (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE). Reflecting the three INCLUDE components of basic science research, cohort development, and clinical trials, the Project has published funding opportunities to address conditions such as immune disorders and Alzheimer's disease...
January 10, 2024: American Journal of Medical Genetics. Part C, Seminars in Medical Genetics
https://read.qxmd.com/read/38190024/acupuncture-versus-oral-medications-for-acute-subacute-non-specific-low-back-pain-a-systematic-review-and-meta-analysis
#14
REVIEW
Huize Lin, Xiang Wang, Yixuan Feng, Xiaoxu Liu, Lanping Liu, Kexin Zhu, Jianghong Shen, Pingping Zhang, Jinna Yu, Tao Yang
PURPOSE OF REVIEW: Pharmacologic intervention do not always achieve benefits in the treatment of acute/subacute non-specific low back pain (NSLBP). We assessed efficacy and safety of acupuncture for acute/subacute NSLBP as alternative treatment. RECENT FINDINGS: We searched PubMed, Web of Science, Embase, Cochrane Library, Scopus, Epistemonikos, CNKI, Wan Fang Database, VIP database, CBMLD, CSTJ, clinical trials, EUCTR, World WHO ICTRP, and ChiCTR for randomized controlled trials, cross-over studies, and cohort studies of NSLBP treated by acupuncture versus oral medication from inception to 23th April 2022...
January 8, 2024: Current Pain and Headache Reports
https://read.qxmd.com/read/38170175/degraders-upgraded-the-rise-of-protacs-in-haematological-malignancies
#15
JOURNAL ARTICLE
Joshua Ml Casan, John F Seymour
Targeted protein degradation (TPD) is a revolutionary approach to targeted therapy in hematological malignancies that potentially circumvents many constraints of existing small molecule inhibitors. Heterobifunctional proteolysis targets chimeras (PROTACs) are the leading TPD drug class, with numerous agents now in clinical trials for a range of blood cancers. PROTACs harness the cell intrinsic protein recycling infrastructure, the ubiquitin-proteasome system (UPS), to completely degrade target proteins. Distinct from targeted small molecule inhibitor therapies, PROTACs can eliminate critical but conventionally 'undruggable' targets, overcome resistance mechanisms to small molecule therapies and can improve tissue specificity and off-target toxicity...
January 3, 2024: Blood
https://read.qxmd.com/read/38167773/long-read-dna-and-rna-sequencing-to-streamline-clinical-genetic-testing-and-reduce-barriers-to-comprehensive-genetic-testing
#16
JOURNAL ARTICLE
Nikhita Damaraju, Angela L Miller, Danny E Miller
BACKGROUND: Obtaining a precise molecular diagnosis through clinical genetic testing provides information about disease prognosis or progression, allows accurate counseling about recurrence risk, and empowers individuals to benefit from precision therapies or take part in N-of-1 trials. Unfortunately, more than half of individuals with a suspected Mendelian condition remain undiagnosed after a comprehensive clinical evaluation, and the results of any individual clinical genetic test ordered during a typical evaluation may take weeks or months to return...
January 3, 2024: Journal of Applied Laboratory Medicine
https://read.qxmd.com/read/38086815/therapeutic-cancer-vaccines-advancements-challenges-and-prospects
#17
REVIEW
Ting Fan, Mingna Zhang, Jingxian Yang, Zhounan Zhu, Wanlu Cao, Chunyan Dong
With the development and regulatory approval of immune checkpoint inhibitors and adoptive cell therapies, cancer immunotherapy has undergone a profound transformation over the past decades. Recently, therapeutic cancer vaccines have shown promise by eliciting de novo T cell responses targeting tumor antigens, including tumor-associated antigens and tumor-specific antigens. The objective was to amplify and diversify the intrinsic repertoire of tumor-specific T cells. However, the complete realization of these capabilities remains an ongoing pursuit...
December 13, 2023: Signal Transduction and Targeted Therapy
https://read.qxmd.com/read/38011968/protocol-for-the-each-trial-a-multicentre-phase-ii-study-evaluating-the-safety-and-antitumour-activity-of-the-combination-of-avelumab-an-anti-pd-l1-agent-and-cetuximab-as-any-line-treatment-for-patients-with-recurrent-metastatic-head-and-neck-squamous-cell
#18
JOURNAL ARTICLE
Kenrick Ng, Rob Metcalf, Joseph Sacco, Anthony Kong, Graham Wheeler, Sharon Forsyth, Reshma Bhat, Joseph Ward, Leah Ensell, Helen Lowe, Victoria Spanswick, John Hartley, Laura White, Elizabeth Lloyd-Dehler, Martin Forster
INTRODUCTION: Head and neck cancer is the eighth most common cancer in the UK. Current standard of care treatment for patients with recurrent/metastatic squamous cell head and neck carcinoma (HNSCC) is platinum-based chemotherapy combined with the anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody, cetuximab. However, most patients will have poor median overall survival (OS) of 6-9 months despite treatment. HNSCC tumours exhibit an immune landscape poised to respond to immunotherapeutic approaches, with most tumours expressing the immunosuppressive receptor programmed death-ligand 1 (PD-L1)...
November 27, 2023: BMJ Open
https://read.qxmd.com/read/37978140/targeting-atr-in-cancer-medicine
#19
JOURNAL ARTICLE
Carolina Salguero, Christian Valladolid, Helen M R Robinson, Graeme C M Smith, Timothy A Yap
As a key component of the DNA Damage Response, the Ataxia telangiectasia and Rad3-related (ATR) protein is a promising druggable target that is currently widely evaluated in phase I-II-III clinical trials as monotherapy and in combinations with other rational antitumor agents, including immunotherapy, DNA repair inhibitors, chemo- and radiotherapy. Ongoing clinical studies for this drug class must address the optimization of the therapeutic window to limit overlapping toxicities and refine the target population that will most likely benefit from ATR inhibition...
2023: Cancer Treatment and Research
https://read.qxmd.com/read/37965606/a-comparative-dataset-bridging-covid-19-and-other-diseases-through-epistemonikos-and-cord-19-evidence
#20
JOURNAL ARTICLE
Andrés Carvallo, Denis Parra, Hans Lobel, Gabriel Rada
The COVID-19 pandemic has underlined the need for reliable information for clinical decision-making and public health policies. As such, evidence-based medicine (EBM) is essential in identifying and evaluating scientific documents pertinent to novel diseases, and the accurate classification of biomedical text is integral to this process. Given this context, we introduce a comprehensive, curated dataset composed of COVID-19-related documents. This dataset includes 20,047 labeled documents that were meticulously classified into five distinct categories: systematic reviews (SR), primary study randomized controlled trials (PS-RCT), primary study non-randomized controlled trials (PS-NRCT), broad synthesis (BS), and excluded (EXC)...
December 2023: Data in Brief
keyword
keyword
89689
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.